IRRAS appoints Dr. Christos Panotopoulos to new role as Special Advisor and a member of the IRRAS Clinical Advisory Board

IRRAS appoints Dr. Christos Panotopoulos to new role as Special Advisor and a member of the IRRAS Clinical Advisory Board

Stockholm, Sweden, May 9, 2018 – IRRAS AB (NASDAQ Stockholm: IRRAS), a commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, today announced that its scientific founder Dr. Christos Panotopoulos, M.D., Ph.D., has been appointed to a new role as Special Advisor and a member of the IRRAS Clinical Advisory Board. Concurrently with his new position, Dr. Panotopoulos will transition from his prior role as Chief Scientific Officer and member of the management team effective June 1, 2018.

“Dr. Christos Panotopoulos is the scientific founder of IRRAS and one of our industry’s leading neurosurgeons. He was instrumental in the development of the company’s products. We are thrilled to appoint Dr Panotopoulos as Special Advisor and a member of the IRRAS Clinical Advisory Board,” said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS. “As our company advances, his clinical work will be strategic to advise IRRAS on the growth of our IRRAflow™ product pipeline. Dr. Panotopoulos will also focus on expanding our network of clinical advisors and further establishing the clinical utility of our products in neurosurgery and other surgical pathologies.”

“I am happy to assist IRRAS in its mission to transform the treatment of intracranial bleedings and look forward to expanding our clinical advisory network as we introduce our products into new pathologies”, said Dr. Panotopoulos. “Since the commercial launch in the EU in May 2017, the ongoing post market survey has demonstrated absence of blockage and infection for more than a hundred consecutive patient treatments in Germany, in different intracranial pathologies.

It is well established that blockage and infection compromise significantly neurosurgical patients’ outcomes and increase significantly patient days in the hospital and costs to hospitals and healthcare providers” continued Dr. Panotopoulos.

For more information, please contact:

Fredrik Alpsten
CFO and Deputy CEO
+46 706 67 31 06
fredrik.alpsten@irras.com
   

About IRRAS

IRRAS AB (NASDAQ Stockholm: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for brain surgery. The Company’s initial product, IRRAflow™, addresses the complications associated with the current treatment methods of intracranial bleeding with a dual lumen catheter that combines active irrigation with ongoing fluid drainage. Regularly during treatment, the catheter is automatically flushed to prevent common catheter occlusions from forming. Additionally, because IRRAflow is a completely closed system, it may also potentially reduce the documented infection risk of these procedures.

With its unique product portfolio, protected by property patents and patent applications, IRRAS is well-positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm with corporate offices in Munich and San Diego. For more information, please visit www.irras.com.
   

This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on May 9, 2018 at 08.05 a.m. (CET).

Tags:

Subscribe

Documents & Links